Skip directly to search Skip directly to A to Z list Skip directly to navigation Skip directly to site content Skip directly to page options
CDC Home

2005 Scientific Articles

2005 Immunization Safety Office Publications

2005 Journal Articles

  1. Baggs J, Chen R, Damon I, Rotz L, Allen C, Fullerton K, Casey CG, Nordenberg D, and Mootrey G. Safety Profile of Smallpox Vaccine: Insights from the Pre-Event Smallpox Vaccination Program. Clin Infect Dis 2005; 40(8): 1133-40.
  2. Belongia EA, Naleway A, Kieke B, Qutaishat S,Casey C, Shay DK, Chen RT. Validation of a Screening Instrument to Identify Persons for Exclusion from Smallpox Vaccination. Clin Infect Dis 2005;40:620-623
  3. Bloom S. Rguig A. Berraho A. Zniber L. Bouazzaoui N. Zaghloul Z. Reef S. Zidouh A. PapaniaM. Seward J.Congenital rubella syndrome burden in Morocco: a rapid retrospective assessment. Lancet. 365(9454):135-41, 2005 Jan 8.
  4. Casey CG, Iskander JK, Roper MH, Mast EE, Wen XJ, Tӧrӧk TJ, Chapman LE, Swerdlow DL, Morgan J, Heffelfinger JD, Vitek C, Reef SE, Hasbrouck LM, Damon I, Neff L, Vellozzi C, McCauley M, Strikas RA, Mootrey G. Adverse Events Associated With Smallpox Vaccination in the United States, January-October 2003. JAMA.2005; 294:2734-2743. http://www.ncbi.nlm.nih.gov/pubmed/16333009
  5. Christine G. Casey; John K. Iskander; Martha H. Roper; Eric E. Mast; Xiao-Jun Wen; Thomas J. Török; Louisa E. Chapman; David L. Swerdlow; Juliette Morgan; James D. Heffelfinger; Charles Vitek; Susan E. Reef; La Mar Hasbrouck; Inger Damon; Linda Neff; Claudia Vellozzi; Mary McCauley; Raymond A. Strikas; Gina Mootrey. Adverse Events Associated With Smallpox Vaccination in the United States, January-October 2003 JAMA.2005;294:2734-2743.
  6. Davis RL, Kolczak M, Lewis E,Nordin J. Goodman M. Shay DK. Platt R. Black S. Shinefield H.ChenRTActive Surveillance of Vaccine Safety Data for Early Signal Detection. Epidemiology,2005;16: 336-341.
  7. DiMiceli L, Pool V, Kelso J.M., Shadomy S.V., Iskander, J. and the VAERS Team.Vaccination of Yeast Sensitive Individuals: Review of Safety Data in the US Vaccine Adverse Event Reporting System (VAERS). Vaccine. 2005 September 8.
  8. Gust, D, Brown, C, Sheedy, K, Hibbs, B, Weaver, D, Nowak,G. Immunization Attitudes and Beliefs Among Parents: Beyond a Dichotomous Perspective. American Journal of Health Behavior, 2005; 29:81-92.
  9. Gust, DA, Kennedy, A, Shui, I, Smith, PJ, Nowak, G, and Pickering, LK. Parent Attitudes Toward Immunizations and Healthcare Providers: The Role of Information. Am J Preventive Health 2005; 29:105-112.
  10. Jackson LA, Neuzil KM, Whitney CG, StarkovichP, Dunstan M, Yu O, Nelson JC, Feikin DR, Shay DK, Baggs J, Carste B, Nahm MH, Carlone G.  Safety of varying dosages of 7-valent pneumococcal protein conjugate vaccine in seniors previously vaccinated with 23-valent pneumococcal polysaccharide vaccine. Vaccine 2005;23(28):3697-703.
  11. Kennedy, A, Brown, C, Gust, D. Vaccine Beliefs of Parents who Support and Oppose Mandatory Vaccination. Public Health Reports, 2005; 120:252-258.
  12. Kennedy, A, Gust, D. Parental vaccine beliefs and child’s school type. Journal of School Health, 2005;75(7):276-280.
  13. Khromava AY. Eidex RB. Weld LH. Kohl KS. Bradshaw RD.ChenRT. Cetron MS. The Yellow Fever Vaccine Safety Working Group.Yellow fever vaccine: an updated assessment of advanced age as a risk factor for serious adverse events. Vaccine. 23(25):3256-63.
  14. Kohl KS, Bonhoeffer J, Braun MM, Chen RT,Duclos P, Heijbel H, Heininger U,Loupi E, Marcy SM. The Brighton Collaboration: A proposal for a global standard of case definitions (and guidelines) for Adverse Events FollowingImmunization.Advances in Patient Safety: From Research to Implementation.Volumes 1-4, AHRQ Publication Nos. 050021 (1-4). February 2005
  15. Martin SW, Tierney BC, Aranas A, Rosenstein NE, Franzke LH, Apicella L, Marano N, and McNeil MM.An Overview of Adverse Events Reported by Participants in CDC’s Anthrax Vaccine and Antibiotics Availability Program. Pharmacoepidemiol. & Drug Saf. 2005;14:393-401. (with a complimentary editorial by E.A. Bresnitz).
  16. Iskander J, Haber P, Herrera G. Monitoring vaccine safety during an influenza pandemic. Yale J Biol Med. 2005; 78(5):265-75.
    http://www.ncbi.nlm.nih.gov/pubmed/17132333
  17. Izurieta Hector, Haber Penina, Wise RobertJohn Iskander; Douglas Pratt; ChrisAnna Mink; Soju Chang; M. Miles Braun; Robert Ball.Early Postmarketing Surveillance of Live, Cold-Adapted, Intranasal Influenza Vaccine. JAMA, Dec 2005.294:2720-2725.
  18. Mandell DS, Thompson WW, Weintraub ES, DeStefano F, Blank MB.Trends in diagnosis rates for autism and ADHD at hospital discharge in the context of other psychiatric diagnoses. Psychiatric Services 2005;56:56–62.
  19. McMahon AW, Iskander J, Haber P, Chang S, Woo EJ, Braun MM, Ball R. Adverse events after inactivated influenza vaccination among children less than 2 years of age: analysis of reports from the vaccine adverse event reporting system, 1990-2003.  Pediatrics 2005;115(2):453-60.
  20. Muralles AA, Ray P,  Black S, Shinefield H,Casey CG,Campbell S, Chen RT and the CISA Network. Active Telephone Surveillance to Evaluate AdverseEvents Among Civilian Smallpox Vaccine Recipients. Vaccine;30 August 2005.
  21. Sejvar J, Boneva R, Lane JM, Iskander J.Severe headaches following smallpox vaccination. (Journal)Headache. 2005 Jan;45(1):87-8.
  22. Sejvar JJ, Labutta RJ, Chapman LE, Grabenstein JD,Iskander J, Lane JM. Neurologic Adverse Events Associated With Smallpox Vaccination in the United States, 2002-2004. JAMA 2005;294 2744-2750.
  23. Shui, I, Kennedy, A, Wooten, K, Schwartz, B, Gust, D. Factors Influencing African American Mothers’ Concernsabout Immunization Safety: A Summary of Focus Group Findings in Atlanta. Journal of the National Medical Association, 2005; 97:657-666.
  24. Vellozzi CJ, Lane MJ, Averhoff F, Mauer T, Norton S, Damon I, Casey C. Generalized vaccinia, progressive vaccinia andeczema vaccinatum are rare following smallpox vaccination: United States Surveillance, 2003. CID 2005;41: 689-69.
  25. Verstraeten T, Davis R, Destefano F. Immunity to tetanus is protective against the development of multiple sclerosis. Med Hypotheses 2005;65(5):966-9.
  26. Yeung LF. Lurie P. Dayan G. Eduardo E. Britz PH. Redd SB.PapaniaMJ. Seward JF.A limited measles outbreak in a highly vaccinated US boarding school.Pediatrics. 116(6):1287-91, 2005 Dec.

Letters/Commentaries/Editorials:

  1. DeStefano F, Weintraub ES, Chen RT.Recombinant hepatitis B vaccine and the risk of multiple sclerosis: a prospective study [letter]. Neurology 2005;64:1317.
  2. Papania MJ, Strebel PM.  Measles surveillance: the importance of finding the tip of the iceberg. Lancet. 2005 Jan 8;365(9454):100-1. (comment)

Top of page

CDC Publications:

MMWR Weekly

  1. CDC. Guillain-Barré Syndrome Among Recipients of Menactra® Meningococcal Conjugate Vaccine—United States, June–July 2005MMWR Dispatch 2005;54:1-3. (Iskander et al.)
  2. Lewis N, Black S, Weintraub E, Baggs J, Thompson W, DeStefano F, Davis R, Shay D. Rapid Assessment of Influenza Vaccination Coverage Among HMO Members—Northern California Influenza Seasons, 2001–02 Through 2004–05. MMWR 2005;54(27):676-678.

Top of page

 
Contact Us:
  • Centers for Disease Control and Prevention
    1600 Clifton Rd
    Atlanta, GA 30333
  • 800-CDC-INFO
    (800-232-4636)
    TTY: (888) 232-6348
  • Contact CDC–INFO
USA.gov: The U.S. Government's Official Web PortalDepartment of Health and Human Services
Centers for Disease Control and Prevention   1600 Clifton Road Atlanta, GA 30329-4027, USA
800-CDC-INFO (800-232-4636) TTY: (888) 232-6348 - Contact CDC–INFO
A-Z Index
  1. A
  2. B
  3. C
  4. D
  5. E
  6. F
  7. G
  8. H
  9. I
  10. J
  11. K
  12. L
  13. M
  14. N
  15. O
  16. P
  17. Q
  18. R
  19. S
  20. T
  21. U
  22. V
  23. W
  24. X
  25. Y
  26. Z
  27. #